Nominations & applications invited for CDRI awards in drug research development
CSIR-Central Drug Research Institute, Lucknow has instituted CDRI Awards to recognise scientific excellence in the country in the area of drug research and development.
These awards are given annually to Indian nationals below 45 years of age who are engaged in basic and applied research in the area having direct bearing on drug research and development and have made outstanding contributions with potential for application/ product and technology development.
There are two separate individual awards each for the area of Chemical Sciences and Life Sciences. Each award carries a cash prize of Rs. 20,000 and a citation.
Head of the Institutions/Organizations/Universities/Industries, Bhatnagar Awardees, Fellows of National Science Academies can nominate. Eligible candidates can also directly submit their application.
Word file of proforma for Nomination/application can be downloaded from http://www.cdri.res.in Complete information must reach CDRI by 31 December 2018 for consideration.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Vertex Shares Plunge 14.4 Percent After Pain Drug Trial Misses Key Target and Study Halt
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
The FDA Officially Blesses AI for Liver Drug Development
Recommend Reading
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
Zydus Brings the First Keytruda Biosimilar Showdown to North America
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
Sodium Hypochlorite: Uses, Concentration Guide, and Critical Safety Hazards
-
Premium Global Chemical Sourcing Requests (19 - 23 Jan, 2026)
-
China Suspends Sulfuric Acid Exports, Global Copper and Fertilizer Supply Under Strain
-
Formic Acid Shows Moving Average Crossover, Upward Momentum Limited
-
Methanol Market Prices Fluctuate Narrowly